Oncology based Molecular Diagnostics Market Analysis By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer) By Product (Instruments, Reagents), By Test Location, By Technology (PCR, Multiplex PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips & Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification) And Segment Forecasts To 2022

Published: Jan, 2016 | Pages: 91 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

Global oncology based molecular diagnostics market is expected to reach USD 3,391.0 million by 2022 according to a new report by Grand View Research Inc. The rising geriatric population base, increasing global prevalence of cancer, rise in sedentary lifestyle adoption levels, and rising awareness & patient education are the driving forces for the oncology based molecular diagnostics market growth over the forecast period.

Growing prevalence of cancer patients owing to adoption of sedentary lifestyles and decrease in immunity levels are estimated to increase industrial growth rate. Furthermore, large variations in both cancer incidence and mortality rates in different sub-regions of developing countries such as Brazil, Mexico, South Africa, and India are also anticipated to enhance the usage of molecular diagnostics to increase survival rates by early detection and validation.

Further key findings from the study suggest:

Breast cancer accounted for largest market share in 2014 with revenue estimated at around USD 170.0 million. Molecular diagnostic assays for breast cancer prognostic are expected to increase the adoption of molecular diagnostics in the near future.
Colorectal cancer is estimated to witness lucrative growth over the forecast period owing to the availability of technologically advanced microarrays & assays such as miRNA microarrays.

On the basis of product, reagents dominated the overall market with a share of over 55% in 2014 owing to high usage rates. Growing initiatives by researchers in this field for detection of disease related novel biomarkers for drug development purpose are estimated to be the key factors attributing to this segment's growth
Clinics and other establishments dominated the overall market in 2014 due to the presence of high procedure volumes and the extensive presence of ancillary support in terms of man power and infrastructure. PoC testing for oncology on the other hand is anticipated to witness significant growth supported by rapidly changing customer preferences.

In situ hybridization was identified as the most preferred molecular diagnostic technique for breast cancer owing to the advantages associated with FISH technology such as accuracy, sensitivity, and speed. It held over 31.0% of the market in 2014. Whereas, PCR was the extensively preferred technique for lung cancer diagnosis in 2014.

Sequencing is estimated to be the fastest growing segment with CAGR estimated at over 19.0% during 2015 to 2022. Development of next generation sequencing techniques providing high throughput analysis and sequencing of genomic data is one of the key drivers for significant growth.
North America on account of the presence of established healthcare infrastructure, high patient awareness levels, increasing disposable income, and high R&D pertaining to drug discovery and development led the market in 2014 in terms of share at over 35.0%

Asia Pacific is also estimated to witness significant growth over the forecast period owing to the presence of a large number of target population, rising awareness levels for cancer detection, and increasing government initiatives in this region enabling the achievement of the largest market share
Key players of this market include Abbott Laboratories, Bayer Healthcare, Becton Dickinson, Cepheid, Danaher Corporation, Gen Probe, Roche Diagnostics, Siemens Healthcare and Sysmex Corporation.

 Table of Contents


Chapter 1 Methodology and Scope
              1.1 Research Methodology
              1.2 Research Scope & Assumptions
              1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Oncology based Molecular diagnostics Industry Outlook
              3.1 Introduction
              3.2 Market Segmentation
              3.3 Market size and growth prospects
              3.4 Oncology based Molecular diagnostics: Market dynamics
                 3.4.1 Market driver analysis
                       3.4.1.1 Increasing prevalence of cancer
                       3.4.1.2 Rising demand for point of care treatment for oncology
                       3.4.1.3 Increasing demand for minimally invasive diagnostic procedures
                       3.4.1.4 Technology advancement
                       3.4.1.5 Growing healthcare expenditure triggering the need for effective diagnostic procedure for cancer
                 3.4.2 Market Restraint Analysis
                       3.4.2.1 High prices of molecular diagnostics tests
                       3.4.2.2 Presence of complicated regulatory framework
              3.5 Key Opportunities Prioritized
              3.6 Industry analysis Porter's
              3.7 Oncology based Molecular diagnostics Market - Company Market Share Analysis, 2014
                 3.8.1 Recommendations for market participants
              3.9 Oncology based Molecular diagnostics: PESTEL Analysis
Chapter 4 Oncology based Molecular diagnostics Type Outlook
              4.1 Oncology based Molecular diagnostics market share by type, 2014 & 2022
              4.2 Breast Cancer
                       4.2.1.1 Breast cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.3 Prostate Cancer
                       4.3.1.1 Prostate cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.4 Colorectal Cancer
                       4.4.1.1 Colorectal cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.5 Cervical Cancer
                       4.5.1.1 Cervical cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.6 Liver Cancer
              4.6.1.1 Liver cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.7 Lung Cancer
                       4.7.1.1 Lung cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.8 Blood Cancer
                       4.8.1.1 Blood cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.9 Kidney Cancer
                       4.9.1.1 Kidney cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
              4.10 Other Cancer
                       4.10.1.1 Other cancer based molecular diagnostics market, 2012 - 2022 (USD Million)
Chapter 5 Oncology based Molecular diagnostics Product Outlook
              5.1 Oncology based Molecular diagnostics market share by product, 2014 & 2022
              5.2 Instruments
                 5.2.1 Instruments market, 2012 - 2022 (USD Million)
              5.3 Reagents
                 5.3.1 Reagents market, 2012 - 2022 (USD Million)
              5.4 Others
                 5.4.1 Others market, 2012 - 2022 (USD Million)
Chapter 6 Molecular diagnostics Test Location Outlook
              6.1 Molecular diagnostics market share by test location, 2014 & 2022
              6.2 Clinics and other establishments
                 6.2.1 Clinics and other establishments market, 2012 - 2022 (USD Million)
              6.3 Point of care
                 6.3.1 Point of care market, 2012 - 2022 (USD Million)
Chapter 7 Oncology based Molecular diagnostics Technology Outlook
              7.1 Oncology based Molecular diagnostics market share by technology, 2014 & 2022
              7.2 PCR
                 7.2.1 PCR market, 2012 - 2022 (USD Million)
                       7.2.1.1 Multiplex market, 2012 - 2022 (USD Million)
                       7.2.1.2 Multiplex PCR market, 2012 - 2022 (USD Million)
                       7.2.1.3 Other market, 2012 - 2022 (USD Million)
              7.3 TMA (Transcription Mediated Amplification)
                 7.3.1 Transcription Mediated Amplification (TMA) market, 2012 - 2022 (USD Million)
              7.4 In Situ Hybridization
                 7.4.1 In situ hybridization market, 2012 - 2022 (USD Million)
              7.5 Sequencing
                 7.5.1 Sequencing market, 2012 - 2022 (USD Million)
              7.6 INAAT (Isothermal Nucleic Acid Amplification Technology)
                 7.6.1 INAAT market, 2012 - 2022 (USD Million)
              7.7 Chips and microarrays
                 7.7.1 Chips and microarrays market, 2012 - 2022 (USD Million)
              7.8 Mass spectrometry
                 7.8.1 Mass spectrometry market, 2012 - 2022 (USD Million)
              7.9 Other technologies
                 7.9.1 Other market, 2012 - 2022 (USD Million)
Chapter 8 Oncology based Molecular diagnostics Regional Outlook
              8.1 Oncology based Molecular diagnostics Revenue Share by Region, 2014& 2022
              8.2 North America
                 8.2.1 North America Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.2.2 U.S.
                 8.2.3 U.S. Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.2.4 Canada
                 8.2.5 Canada Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
              8.3 Europe
                 8.3.1 Europe Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.3.2 UK
                 8.3.3 UK Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.3.4 Germany
                 8.3.5 Germany Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.3.6 France
                 8.3.7 France Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.3.8 Spain
                 8.3.9 Spain Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.3.10 Italy
                 8.3.11 Italy Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
              8.4 Asia Pacific
                 8.4.1 Asia Pacific Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.4.2 Japan
                 8.4.3 Japan Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.4.4 China
                 8.4.5 China Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.4.6 India
                 8.4.7 India Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.4.8 Australia
                 8.4.9 Australia Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.4.10 New Zealand
                 8.4.11 New Zealand Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
              8.5 Latin America
                 8.5.1 Latin America Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.5.2 Brazil
                 8.5.3 Brazil Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.5.4 Mexico
                 8.5.5 Mexico Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.5.6 Colombia
                 8.5.7 Colombia Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
              8.6 MEA
                 8.6.1 MEA Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.6.2 South Africa
                 8.6.3 South Africa Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
                 8.6.4 Saudi Arabia
                 8.6.5 Saudi Arabia Oncology based Molecular diagnostics Market, 2012 - 2022 (USD Million)
Chapter 9 Competitive Landscape
              9.1 Abbott Laboratories
                 9.1.1 Company Overview
                 9.1.2 Financial Performance
                 9.1.3 Product Benchmarking
                 9.1.4 Strategic Initiatives
              9.2 Bayer Healthcare
                 9.2.1 Company Overview
                 9.2.2 Financial Performance
                 9.2.3 Product Benchmarking
                 9.2.4 Strategic Initiatives
              9.3 Becton Dickinson
                 9.3.1 Company Overview
                 9.3.2 Financial Performance
                 9.3.3 Product Benchmarking
                 9.3.4 Strategic Initiatives
              9.4 Cepheid
                 9.4.1 Company Overview
                 9.4.2 Financial Performance
                 9.4.3 Product Benchmarking
                 9.4.4 Strategic Initiatives
              9.5 Dako
                 9.5.1 Company Overview
                 9.5.2 Financial Performance
                 9.5.3 Product Benchmarking
                 9.5.4 Strategic Initiatives
              9.6 Danaher Corporation
                 9.6.1 Company Overview
                       9.6.1.1 Beckman Coulter
                       9.6.1.2 Leica Biosystems
                 9.6.2 Financial Performance
                 9.6.3 Product Benchmarking
                 9.6.4 Strategic Initiatives of Danaher Corporation
                       9.6.4.1 Strategic Initiatives of Beckman Coulter Inc.
                       9.6.4.2 Strategic Initiatives of Leica Biosystems
              9.7 Gen Probe(Hologic)
                 9.7.1 Company Overview
                 9.7.2 Financial Performance
                 9.7.3 Product Benchmarking
              9.8 Qiagen N.V.
                 9.8.1 Company Overview
                 9.8.2 Financial Performance
                 9.8.3 Product Benchmarking
                 9.8.4 Strategic Initiatives
              9.9 Roche Diagnostics
                 9.9.1 Company Overview
                 9.9.2 Financial Performance
                 9.9.3 Product Benchmarking
                 9.9.4 Strategic Initiatives
              9.10 Siemens Healthcare
                 9.10.1 Company Overview
                 9.10.2 Financial Performance
                 9.10.3 Product Benchmarking
                 9.10.4 Strategic Initiatives
              9.11 Sysmex Corporation
                 9.11.1 Company Overview
                 9.11.2 Financial Performance
                 9.11.3 Product Benchmarking
                 9.11.4 Strategic Initiatives

List of Tables


TABLE 1 Oncology based Molecular diagnostics - Industry Snapshot & Key Buying Criteria, 2012 - 2022
TABLE 2 Oncology based Molecular diagnostics market, by type, 2012 - 2022 (USD Million)
TABLE 3 Oncology based Molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 4 Molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 5 Molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 6 Molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 7 Oncology based Molecular diagnostics - Key market driver analysis
TABLE 8 Global cancer incidences, 2012
TABLE 9 North America cancer incidences in 2012
TABLE 10 Europe cancer incidences, 2012
TABLE 11 Asia cancer incidences, 2012
TABLE 12 Africa cancer incidences, 2012
TABLE 13 Australia and New Zealand cancer incidences in 2012
TABLE 14 Oncology : Point of care treatment (POCT)
TABLE 15 Oncology : Molecular diagnostic techniques
TABLE 16 Healthcare expenditure levels, 2012
TABLE 17 Oncology based Molecular diagnostics - Key market restraint analysis
TABLE 18 Global breast cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 19 Global breast cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 20 Global breast cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 21 Global breast cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 22 Global breast cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 23 Global prostate cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 24 Global prostate cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 25 Global prostate cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 26 Global prostate cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 27 Global prostate cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 28 Global colorectal cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 29 Global colorectal cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 30 Global colorectal cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 31 Global colorectal cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 32 Global colorectal cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 33 Global cervical cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 34 Global cervical cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 35 Global cervical cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 36 Global cervical cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 37 Global cervical cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 38 Global liver cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 39 Global liver cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 40 Global liver cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 41 Global liver cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 42 Global liver cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 43 Global lung cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 44 Global lung cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 45 Global lung cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 46 Global lung cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 47 Global lung cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 48 Global blood cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 49 Global blood cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 50 Global blood cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 51 Global blood cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 52 Global blood cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 53 Global kidney cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 54 Global kidney cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 55 Global kidney cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 56 Global kidney cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 57 Global kidney cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)
TABLE 58 Global other cancer based molecular diagnostics market, by product, 2012 - 2022 (USD Million)
TABLE 59 Global other cancer based molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 60 Global other cancer based PCR market, by segments, 2012 to 2022 (USD million)
TABLE 61 Global other cancer based molecular diagnostics market, by test location, 2012 - 2022 (USD Million)
TABLE 62 Global other cancer based molecular diagnostics market, by region, 2012 - 2022 (USD Million)